AR043210A1 - USEFUL TRIAZOL COMPOUNDS IN THERAPY - Google Patents
USEFUL TRIAZOL COMPOUNDS IN THERAPYInfo
- Publication number
- AR043210A1 AR043210A1 ARP040100495A ARP040100495A AR043210A1 AR 043210 A1 AR043210 A1 AR 043210A1 AR P040100495 A ARP040100495 A AR P040100495A AR P040100495 A ARP040100495 A AR P040100495A AR 043210 A1 AR043210 A1 AR 043210A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently represent
- optionally substituted
- ring
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula (1) o un derivado farmacéuticamente aceptable del mismo, donde V representa -(CH2)d(O)e-, -CO- o -CH(alquilo C1-6)-; W es -O-, -S(O)a- o -N(R1)-, R1 representa H, alquilo C1-6, -(CH2)bCOR2, CO(CH2)bNR2R3, SO2R2, (CH2)cOR2, (CH2)cNR2R3 o (CH2)bhet1; het1 representa un heterociclo saturado o insaturado de 3 a 8 átomos que contiene uno o más heteroátomos seleccionados entre O, N o S, opcionalmente sustituido con alquilo C1-6; X e Y representan independientemente H, alquilo C1-6, halógeno, OH, CF3, OCF3, OR4; Z representa -(CH2)f(O)g-, -CO- o -CH(alquilo C1-6)-; El anillo A representa un heterociclo saturado que contiene N de 4-7 miembros, opcionalmente sustituido con OH y en el que opcionalmente al menos un N de anillo está sustituido con O; El anillo B representa fenilo o un heterociclo insaturado que contiene N de 4-7 miembros, opcionalmente sustituido con OH, halógeno, CN, CONH2, CF3, OCF3 y en el que opcionalmente al menos un N de anillo está sustituido con O; R2 y R3 representan independientemente H, alquilo C1-6 [opcionalmente sustituido con OH, halógeno, N(alquilo C1-6)2 o alquiloxi C1-6], alquiloxi C1-6, N(alquilo C1-6)2 o [cicloalquilo C3-8]; o R2 y R3, junto con el átomo de N al que están unidos, representan independientemente un heterociclo de 3 a 8 átomos, opcionalmente sustituido con alquilo C1-6; R4 representa alquilo C1-6 lineal o ramificado, a y c representan independientemente 0, 1 o 2; b, e y g representan independientemente 0 o 1; y d y f representan independientemente 1 o 2; son útiles en el tratamiento de la dismenorrea. Procedimientos para la preparación del compuesto, intermediarios y formulación farmacéutica.A compound of formula (1) or a pharmaceutically acceptable derivative thereof, wherein V represents - (CH2) d (O) e-, -CO- or -CH (C1-6 alkyl) -; W is -O-, -S (O) a- or -N (R1) -, R1 represents H, C1-6 alkyl, - (CH2) bCOR2, CO (CH2) bNR2R3, SO2R2, (CH2) cOR2, ( CH2) cNR2R3 or (CH2) bhet1; het1 represents a saturated or unsaturated heterocycle of 3 to 8 atoms containing one or more heteroatoms selected from O, N or S, optionally substituted with C1-6 alkyl; X and Y independently represent H, C1-6 alkyl, halogen, OH, CF3, OCF3, OR4; Z represents - (CH2) f (O) g-, -CO- or -CH (C1-6 alkyl) -; Ring A represents a saturated heterocycle containing 4-7 membered N, optionally substituted with OH and wherein optionally at least one ring N is substituted with O; Ring B represents phenyl or an unsaturated heterocycle containing 4-7 membered N, optionally substituted with OH, halogen, CN, CONH2, CF3, OCF3 and in which optionally at least one ring N is substituted with O; R2 and R3 independently represent H, C1-6 alkyl [optionally substituted with OH, halogen, N (C1-6 alkyl) 2 or C1-6 alkyloxy], C1-6 alkyloxy, N (C1-6 alkyl) 2 or [cycloalkyl C3-8]; or R2 and R3, together with the N atom to which they are attached, independently represent a heterocycle of 3 to 8 atoms, optionally substituted with C1-6 alkyl; R4 represents linear or branched C1-6 alkyl, a and c independently represent 0, 1 or 2; b, e and g independently represent 0 or 1; and d and f independently represent 1 or 2; They are useful in the treatment of dysmenorrhea. Procedures for the preparation of the compound, intermediates and pharmaceutical formulation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303852.8A GB0303852D0 (en) | 2003-02-19 | 2003-02-19 | Triazole compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043210A1 true AR043210A1 (en) | 2005-07-20 |
Family
ID=9953327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100495A AR043210A1 (en) | 2003-02-19 | 2004-02-18 | USEFUL TRIAZOL COMPOUNDS IN THERAPY |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN1751047A (en) |
| AR (1) | AR043210A1 (en) |
| CL (1) | CL2004000293A1 (en) |
| GB (1) | GB0303852D0 (en) |
| GT (1) | GT200400020A (en) |
| NL (1) | NL1025527C2 (en) |
| PA (1) | PA8596101A1 (en) |
| PE (1) | PE20050222A1 (en) |
| TW (1) | TW200500367A (en) |
| UY (1) | UY28201A1 (en) |
| WO (1) | WO2004074291A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325021D0 (en) * | 2003-10-27 | 2003-12-03 | Pfizer Ltd | Therapeutic combinations |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| DE102004001871A1 (en) * | 2004-01-14 | 2005-09-01 | Bayer Healthcare Ag | Tricyclic benzazepine derivatives and their use |
| JP2008510789A (en) * | 2004-08-25 | 2008-04-10 | ファイザー・インク | Triazolobenzodiazepines and their use as vasopressin antagonists |
| WO2006114706A1 (en) * | 2005-04-26 | 2006-11-02 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| DK2356123T3 (en) | 2008-11-13 | 2012-10-15 | Hoffmann La Roche | SPIRO-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo [e] azulenes |
| CN102216304B (en) * | 2008-11-18 | 2014-07-09 | 弗·哈夫曼-拉罗切有限公司 | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| RU2507205C2 (en) | 2008-11-28 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Arylcyclohexyl esters of dihydrotetraazabenzoazulenes for use as vasopressin v1a receptor antagonists |
| WO2010114894A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| AU2010317842A1 (en) * | 2009-11-16 | 2012-07-12 | Mellitech | [1,5]-diazocin derivatives |
| US8420633B2 (en) * | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) * | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) * | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) * | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) * | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| US9006450B2 (en) * | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| SG188346A1 (en) | 2010-10-07 | 2013-04-30 | Takeda Pharmaceutical | 1,4-oxazepane derivatives |
| RU2011122942A (en) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | NEW KINAZ INHIBITORS |
| US8828989B2 (en) * | 2011-09-26 | 2014-09-09 | Hoffmann-La Roche Inc. | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists |
| KR20140082765A (en) * | 2011-10-05 | 2014-07-02 | 에프. 호프만-라 로슈 아게 | Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
| RS55717B1 (en) | 2012-06-13 | 2017-07-31 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
| CN102766674A (en) * | 2012-07-25 | 2012-11-07 | 辉源生物科技（上海）有限公司 | Establishment of screening platform for cynomolgus monkey antidiuretic hormone receptor V1A antagonist |
| KR102179599B1 (en) | 2012-09-25 | 2020-11-19 | 에프. 호프만-라 로슈 아게 | New bicyclic derivatives |
| AR095079A1 (en) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO |
| PL3035939T3 (en) * | 2013-08-19 | 2020-07-27 | F. Hoffmann-La Roche Ag | V1a antagonists to treat phase shift sleep disorders |
| KR20160087900A (en) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | New octahydro-cyclobuta [1,2-c ; 3,4-c']dipyrrol-2-yl |
| AU2014359409A1 (en) | 2013-12-05 | 2016-05-19 | F. Hoffmann-La Roche Ag | Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof |
| EP3122750B1 (en) | 2014-03-26 | 2019-09-04 | F.Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| PE20161223A1 (en) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | [1,4] DIAZEPINE CONDENSED COMPOUNDS AS INHIBITORS OF THE PRODUCTION OF AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) |
| MA41898A (en) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | BICYCLIC QUINAZOLINONE DERIVATIVES |
| RU2746481C1 (en) | 2015-09-04 | 2021-04-14 | Ф. Хоффманн-Ля Рош Аг | Phenoxymethyl derivatives |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| PE20180451A1 (en) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | NEW BICYCLE COMPOUNDS AS ATX INHIBITORS |
| WO2017050791A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| JP7090099B2 (en) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | A novel bicyclic compound as an ATX inhibitor |
| KR20190129924A (en) | 2017-03-16 | 2019-11-20 | 에프. 호프만-라 로슈 아게 | Heterocyclic Compounds Useful as Dual Autotaxin (ATX) / Carbon Anhydrase (CA) Inhibitors |
| WO2018226769A1 (en) * | 2017-06-05 | 2018-12-13 | Blackthorn Therapeutics, Inc. | 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders |
| TW201938171A (en) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | Tricyclic compounds as vasopressin V1a receptor antagonists |
| HU231206B1 (en) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepines |
| CN111170983B (en) * | 2019-12-26 | 2021-07-09 | 中国农业大学 | Benzylthio acetamide compound and preparation method and application thereof |
| CN114644635B (en) * | 2020-12-21 | 2023-02-03 | 上海济煜医药科技有限公司 | Triazole tricyclic derivative and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823475D0 (en) * | 1988-10-06 | 1988-11-16 | Merck Sharp & Dohme | Chemical compounds |
| US5438035A (en) * | 1994-06-24 | 1995-08-01 | American Cyanamid Company | Methods for controlling undesirable plant species with benzodiazepine compounds |
| US5753648A (en) * | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| DE69725182T2 (en) * | 1996-11-01 | 2004-06-24 | Wyeth | 5H PYRROLO [2,1-c] [1,4] BENZODIAZEPINE-3-CARBOXAMIDE DERIVATIVES |
| IL144270A0 (en) * | 1999-01-19 | 2002-05-23 | Ortho Mcneil Pharm Inc | Tricyclic benzodiazepines as vasopressin receptor antagonists |
| US7109193B2 (en) * | 2001-04-12 | 2006-09-19 | Wyeth | Tricyclic diazepines tocolytic oxytocin receptor antagonists |
-
2003
- 2003-02-19 GB GBGB0303852.8A patent/GB0303852D0/en not_active Ceased
-
2004
- 2004-02-09 WO PCT/IB2004/000432 patent/WO2004074291A1/en active IP Right Grant
- 2004-02-09 CN CNA2004800047089A patent/CN1751047A/en active Pending
- 2004-02-17 PE PE2004000165A patent/PE20050222A1/en not_active Application Discontinuation
- 2004-02-18 CL CL200400293A patent/CL2004000293A1/en unknown
- 2004-02-18 TW TW093103978A patent/TW200500367A/en unknown
- 2004-02-18 PA PA20048596101A patent/PA8596101A1/en unknown
- 2004-02-18 AR ARP040100495A patent/AR043210A1/en not_active Application Discontinuation
- 2004-02-18 GT GT200400020A patent/GT200400020A/en unknown
- 2004-02-19 NL NL1025527A patent/NL1025527C2/en not_active IP Right Cessation
- 2004-02-19 UY UY28201A patent/UY28201A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL1025527A1 (en) | 2004-08-23 |
| GT200400020A (en) | 2004-09-21 |
| CL2004000293A1 (en) | 2005-01-07 |
| GB0303852D0 (en) | 2003-03-26 |
| PA8596101A1 (en) | 2005-08-04 |
| UY28201A1 (en) | 2004-09-30 |
| TW200500367A (en) | 2005-01-01 |
| NL1025527C2 (en) | 2005-03-14 |
| PE20050222A1 (en) | 2005-04-13 |
| WO2004074291A1 (en) | 2004-09-02 |
| CN1751047A (en) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043210A1 (en) | USEFUL TRIAZOL COMPOUNDS IN THERAPY | |
| ECSP055973A (en) | USEFUL TRIAZOL COMPOUNDS IN THERAPY | |
| AR044543A1 (en) | DERIVATIVES OF PIRAZOLO-QUINAZOLINA, A PROCEDURE FOR ITS PREPARATION AND ITS USE AS A QUINASA INHIBITOR | |
| TW200700061A (en) | Organic compounds | |
| AR060159A2 (en) | COMBINATIONS OF COMPOUNDS DERIVED FROM USEFUL TROPANE IN THERAPY | |
| CO5690599A2 (en) | DERIVATIVES OF 3- (4-AMINOFENIL) TIENOPIRIMID-4-ONA AS ANCHANGIST MCH R1 FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY | |
| AR035617A1 (en) | COMPOUNDS DERIVED FROM PHENETHANOLAMINE, COMBINATIONS AND PHARMACEUTICAL FORMULATIONS OF THE SAME, PROCESS FOR THEIR PREPARATION, ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OR PROPHYLAXIS OF A CLINICAL CONDITION FOR WHICH A BETAIEPAR BARDIAR AGENT IS ADDED | |
| NO20064297L (en) | amino alcohol | |
| ECSP045483A (en) | DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR USE | |
| RU2000129161A (en) | DERIVATIVE 1 - [(1-SUBSTITUTED-4-PIPERIDINYL) METHYL] -4-PIPERIDINE, METHOD FOR ITS PRODUCTION, PHARMACEUTICAL COMPOSITION CONTAINING THE INDICATED COMPOUND, AND THE INTERMEDIATE PRODUCT | |
| NO20060110L (en) | Specific glucocorticosteroid compound with anti-inflammatory activity | |
| HUP0100860A2 (en) | Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them | |
| ATE411317T1 (en) | INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | |
| EP1634874A4 (en) | Imidazolidine derivative | |
| AR041246A1 (en) | PIRIDINE DERIVATIVES; A PROCEDURE FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM | |
| AR043259A1 (en) | METHOD FOR THE TREATMENT OF SEVERE CARDIAC INSUFFICIENCY AND MEDICATION FOR IT | |
| JP2002537284A5 (en) | ||
| EA199800013A1 (en) | METHODS OF MINIMIZING OSTEOPOROSIS | |
| AR042887A1 (en) | DERIVATIVES OF DIARILMETIDEN PIPERIDINA PREPARATIONS AND USES OF THE SAME | |
| AR036351A1 (en) | ISOXAZOLOPIRIDINONAS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS | |
| AR041896A1 (en) | DERIVATIVES OF 4 (FENIL-PIPERAZINIL-METIL) BENZAMIDA AND ITS USES FOR THE TREATMENT OF PAIN AND GASTROINTESTINAL DISORDERS | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| ATE185145T1 (en) | 11 BETA-BENZALDOXIM-9 ALPHA, 10 ALPHA-EPOXY-ESTR-4-EN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | |
| DOP2004000827A (en) | USEFUL TRAIZOL COMPOUNDS IN THERAPY | |
| ATE172959T1 (en) | ACYLPHENYLGLYCINE DERIVATIVE AND PREVENTIVE AND CURE AGAINST DISEASES CAUSED BY INCREASED COLLAGENOSE ACTIVITY CONTAINING THIS AS AN ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |